XanaMIA Study
XanaMIA is a randomised clinical trial investigating the effectiveness of oral Xanamem 10mg vs placebo daily in participants with mild or moderate Alzheimer's Disease.
Healthy elderly people with elevated cortisol levels are significantly more likely to develop AD than those with low cortisol levels. Therefore Xanamem is proposed to block excess production of cortisol in the brain.
Each study site for this trial has it's own ethical approval.
Participation
To be suitable for this trial you must meet the below criteria:
- 50+ years of age
- Diagnosis of Alzheimer's disease
- MMSE between 18-26
- Have not received an anti-amyloid therapy in the last 6 months
- Have a study partner who can attend appointments with you
If you are interested in participating or would like to find out more please contact the research team (details below).
Participant duration
The XanaMIA study lasts for 12 months and involves 11 visits to our clinic and two phone calls
Available to people living in
All states and territories
Study begins
Monday, 26 February 2024
Study ends
Wednesday, 31 December 2025
Contact
To find out more about this study, contact:
Natasha Masand
Actinogen
clinicaltrials@actinogen.com.au
All states and territories
